{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:02:34Z","timestamp":1792688554587,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.schres.2023.08.023","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:36:48Z","timestamp":1694432208000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data"],"prefix":"10.1016","volume":"260","author":[{"given":"Rashmi","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily O.C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Valko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprabha","family":"Guruswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel E.","family":"Renter\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1017\/S0033291713000548","article-title":"Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors","volume":"44","author":"Bahorik","year":"2014","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.schres.2023.08.023_bb0010","doi-asserted-by":"crossref","DOI":"10.1097\/01.jcp.0000169419.38899.5b","article-title":"Aripiprazole in schizophrenia with cocaine dependence: a pilot study","volume":"25","author":"Beresford","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2023.08.023_bb0015","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1176\/appi.ajp.162.8.1483","article-title":"Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress","volume":"162","author":"Brady","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.08.023_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.0706e01","article-title":"Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness","volume":"67","author":"Buckley","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2023.08.023_bb0025","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000788","article-title":"Strengths and weaknesses of \u2018real-world\u2019 studies involving non-vitamin K antagonist oral anticoagulants","volume":"5","author":"Camm","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.schres.2023.08.023_bb0035","series-title":"UpToDate","article-title":"Pharmacotherapy for co-occurring schizophrenia and substance use disorder","author":"Campbell","year":"2023"},{"issue":"6","key":"10.1016\/j.schres.2023.08.023_bb0040","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The economic burden of schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.08.023_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"issue":"3","key":"10.1016\/j.schres.2023.08.023_bb0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000355267","article-title":"Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review","volume":"20","author":"De Witte","year":"2014","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.schres.2023.08.023_bb0055","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0920-9964(98)00161-3","article-title":"Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes","volume":"35","author":"Dixon","year":"1999","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2023.08.023_bb0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2014.04.033","article-title":"Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: effects of cannabis and THC","volume":"158","author":"Fischer","year":"2014","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2023.08.023_bb0065","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1017\/S0033291717000046","article-title":"Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis","volume":"47","author":"Foglia","year":"2017","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2023.08.023_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/oxfordjournals.schbul.a033339","article-title":"Patterns of current and lifetime substance use in schizophrenia","volume":"24","author":"Fowler","year":"1998","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2023.08.023_bb0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2003.08.001","article-title":"First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol","volume":"66","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.08.023_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.schres.2023.08.023_bb0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.psychres.2014.12.006","article-title":"Comorbid substance use disorders in schizophrenia: a latent class approach","volume":"225","author":"Kerner","year":"2015","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archgenpsychiatry.2010.180","article-title":"Development of lifetime comorbidity in the World Health Organization world mental health surveys","volume":"68","author":"Kessler","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2023.08.023_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.comppsych.2018.12.004","article-title":"The association between comorbid psychiatric diagnoses and hospitalization-related factors among individuals with schizophrenia","volume":"89","author":"Kessler","year":"2019","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/acps.13291","article-title":"Morbidity and mortality in schizophrenia with comorbid substance use disorders","volume":"144","author":"L\u00e4hteenvuo","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2023.08.023_bb0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0447.2005.00554.x","article-title":"The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis","volume":"112","author":"Lambert","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2023.08.023_bb0110","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1002\/gps.4799","article-title":"The impact of substance use disorders on clinical outcomes in older-adult psychiatric inpatients","volume":"33","author":"Lane","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0975-9727.112264","article-title":"Medical comorbidity in in-patients with psychiatric disorder","volume":"4","author":"Manuel","year":"2013","journal-title":"Muller J. Med. Sci. Res."},{"issue":"9","key":"10.1016\/j.schres.2023.08.023_bb0120","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0004867412443900","article-title":"The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis","volume":"46","author":"Moore","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.08.023_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2023.08.023_bb0130","series-title":"Schizophrenia","author":"National Institute of Mental Health","year":"2022"},{"key":"10.1016\/j.schres.2023.08.023_bb0135","series-title":"Medication Noncompliance and Substance Abuse among Patients with Schizophrenia","author":"Owen","year":"1996"},{"issue":"6","key":"10.1016\/j.schres.2023.08.023_bb0140","first-page":"678","article-title":"High utilizers of psychiatric emergency services","volume":"56","author":"Pasic","year":"2005","journal-title":"Psychiatry Online"},{"issue":"3","key":"10.1016\/j.schres.2023.08.023_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009888","article-title":"Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study","volume":"6","author":"Patel","year":"2016","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.schres.2023.08.023_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057227","article-title":"NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data","volume":"12","author":"Patel","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.schres.2023.08.023_bb0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2020.11.002","article-title":"Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study","volume":"224","author":"Patel","year":"2020","journal-title":"Schizophr. Res."},{"issue":"1\u20132","key":"10.1016\/j.schres.2023.08.023_bb0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2016.03.011","article-title":"Increased ventro-medial prefrontal activations in schizophrenia smokers during cigarette cravings","volume":"173","author":"Potvin","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2023.08.023_bb0165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/appi.ps.51.2.210","article-title":"Shorter hospital stays and more rapid improvement among patients with schiozophrenia and substance disorders","volume":"51","author":"Ries","year":"2000","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.schres.2011.04.011","article-title":"The impact of substance use disorders on the course of schizophrenia\u2014a 15-year follow-up study: dual diagnosis over 15\u00a0years","volume":"130","author":"Schmidt","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.08.023_bb0175","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/mp.2012.109","article-title":"Striatal dopamine release in schizophrenia comorbid with substance dependence","volume":"18","author":"Thompson","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.08.023_bb0180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1192\/bjp.bp.108.057471","article-title":"Impact of persistent substance misuse on 1-year outcome in first-episode psychosis","volume":"195","author":"Turkington","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.08.023_bb0185","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.pnpbp.2008.02.008","article-title":"Pharmacotherapy of schizophrenia with comorbid substance use disorder\u2014reviewing the evidence and clinical recommendations","volume":"32","author":"Wobrock","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/NMD.0000000000000231","article-title":"Hospital length of stay in individuals with schizophrenia with and without cocaine-positive urine drug screens at hospital admission","volume":"203","author":"Wu","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.schres.2023.08.023_bb0195","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-200002000-00016","article-title":"Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey","volume":"20","author":"Zimmet","year":"2000","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:55:00Z","timestamp":1760298900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423002918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":39,"alternative-id":["S0920996423002918"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.08.023","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}